SCHEMBL1849150

SCHEMBL1849150

O=Cc1cc2cccc(Br)c2s1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2A6 P11509 8/20 0.52
CHRNA1 P02708 1/20 0.36
CHRNB2 P17787 1/20 0.36
CHRNB4 P30926 1/20 0.36
CHRNA4 P43681 1/20 0.36
ALDH1A1 P00352 1/20 0.34
CA2 P00918 2/20 0.34
PSMB8 P28062 1/20 0.33
HDAC3 O15379 2/20 0.33
HDAC4 P56524 2/20 0.33
HDAC1 Q13547 2/20 0.33
HDAC7 Q8WUI4 2/20 0.33
HDAC2 Q92769 2/20 0.33
HDAC10 Q969S8 2/20 0.33
HDAC11 Q96DB2 2/20 0.33
HDAC8 Q9BY41 2/20 0.33
HDAC6 Q9UBN7 2/20 0.33
HDAC9 Q9UKV0 2/20 0.33
HDAC5 Q9UQL6 2/20 0.33
CTRC Q99895 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30581207 1.00 CYP2A6 (0.52) CYP2A6CHRNA1CHRNB2CHRNB4CHRNA4
SCHEMBL3610464 0.78 CYP2A6 (0.52) CYP2A6ALDH1A1PSMB8HDAC3HDAC4
SCHEMBL29196077 0.78 CA2 (0.53) CYP2A6ALDH1A1CA2
SCHEMBL12095234 0.78 CYP2A6 (0.52) CYP2A6HDAC3HDAC4HDAC1HDAC7
SCHEMBL13195264 0.78 CYP2A6 (0.52) CYP2A6ALDH1A1
SCHEMBL16686631 0.77 KDM4E (0.36) CHRNA1CHRNB2CHRNB4CHRNA4ALDH1A1
SCHEMBL16686632 0.77 KDM4E (0.36) CHRNA1CHRNB2CHRNB4CHRNA4ALDH1A1
SCHEMBL9526357 0.74 CYP2A6 (0.56) CYP2A6ALDH1A1
SCHEMBL23500126 0.74 PSMB8 (0.38) CYP2A6CHRNA1CHRNB2CHRNB4CHRNA4
SCHEMBL16693056 0.74 CYP2A6 (0.47) CYP2A6ALDH1A1CA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-116640152-A Benzothiophene pyridine derivative and synthesis method thereof 西安欧得光电材料有限公司 2023-08-25 CN claimed
EP-4743174-A1 MODULATORS OF CALCITONIN RECEPTOR AND/OR AMYLIN RECEPTOR ACTIVITY Aconcagua Bio, Inc. (US) 2026-05-20 EP disclosed
US-20250042916-A1 COMPOUNDS, COMPOSITIONS, AND METHODS ACONCAGUA BIO, INC. 2025-02-06 US disclosed
WO-2025015268-A1 MODULATORS OF CALCITONIN RECEPTOR AND/OR AMYLIN RECEPTOR ACTIVITY ACONCAGUA BIO, INC. (US) 2025-01-16 WO disclosed
CN-118255815-A Organic metal compound, preparation method thereof and light-emitting device 吉林奥来德光电材料股份有限公司 2024-06-28 CN disclosed
CN-116640152-A Benzothiophene pyridine derivative and synthesis method thereof 西安欧得光电材料有限公司 2023-08-25 CN disclosed
CN-108299425-B Fused ring derivative, preparation method, intermediate, pharmaceutical composition and application thereof 上海璎黎药业有限公司 2020-09-18 CN disclosed
CN-108516958-B Fused ring derivative, preparation method, intermediate, pharmaceutical composition and application thereof 上海璎黎药业有限公司 2020-07-17 CN disclosed
EP-3275867-B1 PYRIDO-FUSED BICYCLIC COMPOUNDS AS URAT1 INHIBITORS FOR TREATING HYPERURICEMIA SHANGHAI YINGLI PHARM CO LTD (CN) 2020-06-10 EP disclosed
EP-3275867-B1 PYRIDO-FUSED BICYCLIC COMPOUNDS AS URAT1 INHIBITORS FOR TREATING HYPERURICEMIA SHANGHAI YINGLI PHARM CO LTD (CN) 2020-06-10 EP disclosed
CN-106008340-A Fused ring derivative, preparation method, intermediate, pharmaceutical composition and application thereof 上海璎黎药业有限公司 2016-10-12 CN disclosed
WO-2016150255-A1 CONDENSED RING DERIVATIVE, AND PREPARATION METHOD, INTERMEDIATE, PHARMACEUTICAL COMPOSITION AND USE THEREOF 上海璎黎药业有限公司 2016-09-29 WO disclosed
WO-2015066371-A1 SPIRO-OXADIAZOLINE COMPOUNDS AS AGONISTS OF α-7-NICOTINIC ACETYLCHOLINE RECEPTORS FORUM PHARMACEUTICALS, INC. (US) 2015-05-07 WO disclosed
WO-2015066371-A1 SPIRO-OXADIAZOLINE COMPOUNDS AS AGONISTS OF α-7-NICOTINIC ACETYLCHOLINE RECEPTORS FORUM PHARMACEUTICALS, INC. (US) 2015-05-07 WO disclosed
EP-2323978-A1 AMIDE COMPOUND Takeda Pharmaceutical Company Limited (JP) 2011-05-25 EP disclosed
WO-2010018874-A1 AMIDE COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-02-18 WO disclosed
US-20100041891-A1 AMIDE COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-02-18 US disclosed
US-20040122001-A1 Pharmaceutical compounds ELI LILLY AND COMPANY 2004-06-24 US disclosed
EP-1345930-A2 PHARMACEUTICAL COMPOUNDS ELI LILLY AND COMPANY (US) 2003-09-24 EP disclosed
WO-2002050067-A2 PHARMACEUTICAL HETEROCYCLIC COMPOUNDS ELI LILLY AND COMPANY (US) 2002-06-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100041891-A1 AMIDE COMPOUND GPR52, GPR132, NR5A2 CYP2A6 893/4885CHRNA1 21/4885CHRNB2 43/4885
US-20040122001-A1 Pharmaceutical compounds CYP2D6, LPXN, CYP1B1 CYP2A6 39/4885CHRNA1 830/4885CHRNB2 3143/4885
US-20250042916-A1 COMPOUNDS, COMPOSITIONS, AND METHODS IAPP, GIPR, GPR119 CYP2A6 3708/4885CHRNA1 83/4885CHRNB2 43/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.